New Long Covid trials aim to clear lingering virus—and help patients in dire need.
Comments closedTag: medical treatments
New antibody treatment for RSV in infants highly effective in reducing hospitalisations
A new antibody treatment could reduce by 80 per cent the numbers of babies and young children admitted to hospital with respiratory syncytial virus (RSV), a “groundbreaking” study has found.
Published in the New England Journal of Medicine on Thursday, the study involved 8,058 healthy babies aged up to 12 months from the UK, France and Germany, who were approaching their first RSV season. Half were randomly assigned to receive the antibody nirsevimab by injection, while 4,021 babies received standard care.
Of the babies who received the treatment, only 11 (0.3 per cent) were hospitalised, in comparison with the 60 babies (1.5 per cent) who were hospitalised after receiving just the standard care.
Comments closedLe mystère entourant la COVID longue limite les capacités de traitements
Four years after the first cases of what was later called COVID-19, infections continue to spread and lead to new cases of long COVID. However,…
Comments closedIvermectin warnings, a new COVID-19 antiviral, a changing threshold for care: These are the WHO’s updated treatment guidelines
The World Health Organization (WHO) has updated its guidelines for the treatment of COVID-19 patients, including categories of hospitalization risk to help doctors tailor treatment, and recommendations surrounding a new antiviral designed specifically to tackle the disease.
Comments closedUn médicament québécois démontre son efficacité contre la COVID-19
A cocktail of antibodies developed by the Quebec company Immune Biosolutions has proven its effectiveness in relieving respiratory symptoms caused by COVID-19 in the acute phase of the disease.
Comments closed